Summary
Creutzfeldt-Jakob disease is a rare, fatal neurodegenerative disease characterised by spongiform encephalopathy and transmissibility. The majority of cases of the disease occur sporadically with no known causation. However, in a small number of well documented cases, the disease has developed following the use of cadaver-derived products, or after neurosurgical procedures with instruments previously used in intracranial operations on patients with Creutzfeldt-Jakob disease. Routine processing of this presumably contaminated material or the routine sterilisation of these instruments appears to have been inadequate in abolishing the viability of the agent causing the disease. Host genetic factors are also implicated in the susceptibility to iatrogenic disease.
The variety of iatrogenic mechanisms by which Creutzfeldt-Jakob disease can be acquired emphasises the need for continued vigilance, and the careful assessment of benefit versus risk in any therapy based on human material, particularly when derived from the CNS.
Similar content being viewed by others
References
Will RG, Matthews WB. A retrospective study of Creutz-feldt-Jakob disease in England and Wales 1970-79 I: Clinical features. J Neurol Neurosurg Psychiatry 1984; 47: 134–40
Bell JE, Ironside JW. Neuropathology of spongiform encephalopathies in humans. Br Med Bull 1993: 49; 738–77
Gibbs Jr CJ, Gajdusek DC, Asher DM, et al. Creutzfeldt-Jakob disease (spongiform encephalopathy). Transmission to the chimpanzee. Science 1968; 161: 388–9
Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977; 197: 943–60
Galvez S, Masters C, Gajdusek DC. Descriptive epidemiology of Creutzfeldt-Jakob disease in Chile. Arch Neurol 1980; 37: 11–4
Tsuji S, Kuroiwa Y. Creutzfeldt-Jakob Disease in Japan. Neurology 1983; 33: 1503–6
Brown P, Cathala F, Raubertas RF, et al. The epidemiology of Creutzfeldt-Jakob disease. Conclusions of a 15 year investigation in France and review of the world literature. Neurology 1987; 37: 895–904
Harries-Jones R, Knight R, Will RG, et al. Creutzfeldt-Jakob disease in England and Wales, 1980–84: A case-control study of potential risk factors. J Neurol Neurosurg Psychiatry 1988; 51: 1113–9
Oesch B, Westaway D, Walchli M, et al. A cellular gene encodes scrapie PrP 27–30 protein. Cell 1985; 40: 735–46
Masters CL, Gajdusek DC, Gibbs Jr CJ. The familial occurrence of Creutzfeldt-Jakob disease and Alzheimer’s disease. Brain 1981; 104: 535–58
Palmer MS, Collinge J. Human prion diseases. In: Rossor MN, editor. Bailliere’s clinical neurology, vol. 1, no. 3. London: Bailliere Tindall, 1992: 627–51
Palmer MS, Dryden AJ, Hughes JT, et al. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease [letter]. Nature 1991; 352: 340–1
Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 1991; 337: 1441–2
Gibbs Jr CJ, Joy A, Heffner R, et al. Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone. N Engl J Med 1985; 313(12): 734–8
Fradkin JE, Schonberger LB, Mills JL, et al. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 1991; 265: 880–4
Healy DL, Evans J. Creutzfeldt-Jakob disease after pituitary gonadotrophins. BMJ 1993; 307: 517–8
Brown P. The clinical neurology and epidemiology of Creutzfeldt-Jakob disease, with special reference to iatrogenic cases. In: Bock G, Marsh J, editors. Novel infectious agents and the central nervous system. Chichester: John Wiley & Sons, 1988: 3–23
Brown P, Preece MA, Will RG. ‘Friendly fire’ in medicine: Hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992; 340: 24–7
Pocchiari M, Peano S, Conz A, et al. Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. Horm Res 1991; 35: 161–6
Brown P, Cervenáková L, Goldfarb LG, et al. Iatrogenic Creutzfeldt-Jakob disease: An example of the interplay between ancient genes and modern medicine. Neurology 1994; 44: 291–3
Esmonde T, Lueck CJ, Symon L, et al. Creutzfeldt-Jakob disease and lyophilised dura mater grafts: report of two cases. J Neurol Neurosurg Psychiatry 1993; 56: 999–1000
Anonymous. Creutzfeldt-Jakob disease in patients who received a cadaveric dura mater graft — Spain, 1985–1992. MMWR Morb Mortal Wkly Rep 1993; 42 (28): 560–3
Takayama S, Hatsuda N, Matsumara K, et al. Creutzfeldt-Jakob disease transmitted by cadaveric dural graft: a case report. No Shinkei Geka 1993; 21(2): 167–70
Duffy P, Wolf J, Collins G, et al. Possible person-to-person transmission of Creutzfeldt-Jakob disease [letter]. N Engl J Med 1974; 290: 692
Manuelidis EE, Angelo JN, Gorgacz EJ, et al. Experimental Creutzfeldt-Jakob disease transmitted via the eye with infected cornea. N Engl J Med 1977; 296: 1334–6
Liberski PP, Yanagihara R, Gibbs Jr CJ, et al. Spread of Creutzfeldt-Jakob disease virus along visual pathways after intraocular inoculation. Arch Virol 1990; 111: 141–7
Bernoulli C, Siegfried J, Baumgartner G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery [letter]. Lancet 1977; 1: 478–9
Will RG, Matthews WB. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1982; 45: 235–8
Jones DP, Nevin S. Rapidly progressive cerebral degeneration (subacute vascular encephalopathy) with mental disorder, focal disturbances and myoclonic epilepsy. J Neurol Neurosurg Psychiatry 1954; 17: 148–59
Nevin S, McMenemy WH, Behrman S, et al. Subacute spongiform encephalopathy — a subacute form of encephalopathy attributed to vascular dysfunction (spongiform cerebral atrophy). Brain 1960; 83: 519–64
Masters CL, Harris JO, Gajdusek DC, et al. Creutzfeldt-Jakob disease: Patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979; 5: 177–88
Foncin JF, Gaches J, Cathala F, et al. Transmission iatrogéne interhumaine possible de maladie de Creutzfeldt-Jakob avec atteinte des grains du cervelet. Rev Neurol (Paris) 1980; 136(3): 280
Department of Health and Social Security. Management of patients with spongiform encephalopathy (Creutzfeldt-Jakob disease [CJD]). London: HM Stationery Office, 1984: circular DA (84) 16
Ayliffe GAJ. Surgical instruments and disease transmission [letter]. Lancet 1993; 341: 1098
Tange RA, Troost D, Limburg M. Progressive fatal dementia (Creutzfeldt-Jakob disease) in a patient who received homograft tissue for tympanic membrane closure. Eur Arch Otorhinolaryngol 1990; 247: 199–201
Klein R, Dumble LJ. Transmission of Creutzfeldt-Jakob disease by blood transfusion [letter]. Lancet 1993; 341: 768
Wigley RD. Moratorium on Kveim tests [letter]. Lancet 1993; 341: 1284
Esmonde TFG, Will RG, Slattery JM, et al. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1993; 341: 205–7
Heye N, Hensen S, Müller N. Creutzfeldt-Jakob disease and blood transfusion [letter]. Lancet 1994; 343: 298–9
de Silva RN, Will RG. Moratorium on Kveim test [letter]. Lancet 1993; 342: 173
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Silva, R., Esmonde, T. Iatrogenic Transmission of Creutzfeldt-Jakob Disease. CNS Drugs 2, 96–101 (1994). https://doi.org/10.2165/00023210-199402020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199402020-00002